Investor Login
     The DRI team was professional, collaborative and responsive throughout the process, and we’re pleased to have completed this transaction with them.
- Steven H. Holtzman, Executive Vice President, Corporate Development at Biogen Idec
Portfolio

DRI Capital, through its managed funds, has purchased over 60 royalty streams from some of the world’s leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. As a result of these transactions, DRI Capital, through its managed funds, owns royalties on some of the best-selling biopharmaceutical products in the world including Enbrel, Keytruda, Myozyme, Remicade, Sensipar, Simponi, Stelara, Tysabri and Zytiga among many others.